Eibhlin Mulroe

Ms Mulroe was appointed CEO of the Cancer Trials Ireland (formerly ICORG) in June 2015 and manages a cross functional team in Head Office of 50 staff including clinical operations, Data & Statistics, Quality and Pharmacovigilance. She works to implement the strategic plan in consultation with the Dr Jonathan Westrup, Chair of the Board of Directors and Prof Bryan Hennessy, Clinical Lead. Under her leadership, Cancer Trials Ireland rebranded, moved to a bespoke office space, commissioned an Economic Impact Report (DFK) on cancer trial activity in Ireland, worked with InterTrade Ireland in 2017/8 to revisit the all-Ireland cancer trials network and established a Patient Advocate Advisory Group.

Cancer Trials Ireland is a not for profit organisation with a mission to bring Irish patients early access to the latest cancer treatments through research and to establish Ireland as a recognised centre of high quality translational and clinical research.

​​

Ms Mulroe sits on the Ehealth Ireland Committee which supports the implementation of the Irish government’s Ehealth Strategy. She is a member of the Royal Irish Academy Life Sciences Committee. A member of the Governance Committee of Blood Cancer Network Ireland (BCNI). The Irish Health Research Forum appointed Ms Mulroe to their Steering Group in 2018. A member of the Advisory Board of the Cork Clinical Research Centre. She leads the organisations advocacy agenda where the National Cancer Strategy has dominated discussions with relevant individuals at the Department of Health, IDA, National Cancer Control Programme (NCCP) and HSE.

​​

In her early career Ms Mulroe worked in Irish Politics and then the NGO sector where she worked as CEO of the Asthma Society of Ireland. She then worked as an Account Manager with MedMedia working on marketing campaigns with corporate clients.

​

In July 2007, she became the first CEO of the Irish Platform for Patients' Organisations, Science and Industry (IPPOSI) and Chair of a Task Force in the European Patient Academy for Therapeutic Innovation (EUPATI). Ms Mulroe was appointed by the Irish Minister for Health to the Department of Health Steering Group on Rare Disease Policy in 2010, she represented patients on the Health Information and Quality Authority (HIQA) Research Ethics Advisory Board, HIQA, HTA Advisory Board and was a member of the HSE Patient’s Forum. She served as the patient representative on the Legal Consultative Panel of the Irish Medicines Board (now HPRA). Ms Mulroe led IPPOSI to partake in 2 EC Research Consortiums, BBMRI and EUPATI, the latter is a unique initiative to develop an EU Patient Academy.

​​

Ms Mulroe has a BSocSc Hons from Queens University Belfast and is an MBA graduate from the Smurfit Business School, University College Dublin.